AstraZenecaMEX:AZN1N 84 EV-to-FCF is 38.26 as of Jul. 02, 2026, which is 18% below its 10-year median of 46.38. GuruFocus rates MEX:AZN1N with a GF Score™ of 84/100 and a GF Value™ of MXN3,171.07 (Fairly Valued). The stock has 3 warning signs investors should review. Among 561 Drug Manufacturers companies, AstraZeneca ranks worse than 69.16% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, AstraZeneca's Enterprise Value is MXN5,429,621 Mil.
AstraZeneca's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was MXN141,898 Mil. Therefore, AstraZeneca's EV-to-FCF for today is 38.26.
The historical rank and industry rank for AstraZeneca's EV-to-FCF or its related term are showing as below:
MEX:AZN1N'
s EV-to-FCF Range Over the Past 10 Years
Min: -1238.61 Med: 46.38 Max: 267.74
Current: 40.8
During the past 13 years, the highest EV-to-FCF of AstraZeneca was 267.74. The lowest was -1238.61. And the median was 46.38.
MEX:AZN1N's EV-to-FCF is ranked worse than 69.16% of 561
companies
in the Drug Manufacturers industry
Industry Median: 20.16
vs MEX:AZN1N: 40.80
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
AstraZeneca's PE Ratio (TTM) for today is calculated as:
AstraZeneca's share price for today is MXN3263.65.
AstraZeneca's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN121.730.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
AstraZeneca EV-to-FCF Related Terms
AstraZeneca EV-to-FCF Historical Data
* Premium members only.
The historical data trend for AstraZeneca's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, AstraZeneca's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AstraZeneca EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where AstraZeneca's EV-to-FCF falls into.
AstraZeneca's current Enterprise Value is MXN5,429,621 Mil.
AstraZeneca's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN141,898 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AstraZeneca (MEX:AZN1N) has a EV-to-FCF of 38.26 as of Jul. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on AstraZeneca and its competitors. This is 18% below median its historical median of 46.38. According to the industry distribution chart, AstraZeneca ranks #388 out of 561 companies in the Drug Manufacturers industry, placing it in the top 69.2%.
Is AstraZeneca's EV-to-FCF too high?
AstraZeneca's current EV-to-FCF of 38.26 is 18% below median its 10-year median of 46.38. The Drug Manufacturers industry median EV-to-FCF is 20.16. AstraZeneca's value of 38.26 is 89.8% above this industry median. Based on the distribution chart, AstraZeneca ranks #388 out of 561 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, AstraZeneca has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca's EV-to-FCF compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, AstraZeneca ranks #388 out of 561 companies for EV-to-FCF. This places AstraZeneca in the lower half of its industry. The industry median EV-to-FCF is 20.16. AstraZeneca's value of 38.26 is 89.8% above this benchmark. While the company's 10-year median is 46.38 vs. the industry median of 20.16, AstraZeneca has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.16, based on 561 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AstraZeneca's current EV-to-FCF of 38.26 is 89.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on AstraZeneca and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AstraZeneca's current EV-to-FCF is 38.26, which is 18% below median its own 10-year median of 46.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca (MEX:AZN1N) is currently considered Fairly Valued. The stock's GF Value™ is MXN3,171.07, compared to a current price of MXN3,263.65 — trading 2.9% above its estimated fair value. The current EV-to-FCF is 38.26, which is 18% below median its 10-year median of 46.38 and 89.8% above the Drug Manufacturers industry median of 20.16. AstraZeneca's overall GF Score™ is 84/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For AstraZeneca (MEX:AZN1N), the current EV-to-FCF is 38.26 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AstraZeneca (MEX:AZN1N) Overvalued in 2026?
Based on GuruFocus' analysis, AstraZeneca stock appears to be overvalued.
The current stock price of MXN3,263.65 is trading 2.9% above its estimated GF Value™ of MXN3,171.07.
GuruFocus considers AstraZeneca to be Fairly Valued.
Key valuation signals for MEX:AZN1N:
EV-to-FCF: 38.26 (18% below median its 10-year median of 46.38)
GF Value™: MXN3,171.07 vs. price of MXN3,263.65 (2.9% above fair value)
Industry Position: 89.8% above the Drug Manufacturers median (#388 of 561)
No single metric tells the full story. See the MEX:AZN1N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
84GF Score
Get the complete analysis for MEX:AZN1N
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:AZN1N has been successfully added to your 
